Home » Market News » DirectorsTalk Highlights » Allergy Therapeutics will transform allergy treatment, formulated to the optimal strength.
Allergy therapeutics plc

Allergy Therapeutics will transform allergy treatment, formulated to the optimal strength.

Allergy Therapeutics (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, said today that a satellite symposium entitled: “The Best Therapies by Design” was held at the 36(th) Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Helsinki, Finland on 18 June 2017, providing an overview of the technologies and strategies involved in designing the best immunotherapies.

Chaired by Professor Stephen Durham, four world-leading experts in the field of allergy, pollen, and immunotherapy vaccine delivery, Jörg Kleine-Tebbe, Erika Jensen-Jarolim, Uwe Berger & Tim Higenbottam presented on the strategy, design and considerations involved in creating immunotherapies such as Allergy Therapeutics’ flagship product, Pollinex Quattro(R). Uwe Berger and Erika Jensen-Jarolim discussed the importance of highlighting relevant allergens and characterising them sufficiently. Jörg Kleine-Tebbe discussed why successful immunotherapy requires identification of the optimal dose before Phase III studies are begun, before Tim Higenbottam finished the session describing the results recently gained from the Group’s clinical studies.

Manuel Llobet, Chief Executive Officer , commented Allergy Therapeutics (LON:AGY): “We are delighted with our progress in developing the next generation of allergen immunotherapy products. Our latest clinical data on dose-ranging confirms that our unique allergen-specific immunotherapies are formulated to the optimal strength and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free products.”

Satellite Symposium: “The Best Therapies by Design”

1. The importance of defining the optimal dose – Jörg Kleine-Tebbe, Allergie und Asthma – Zentrum Westend, Berlin.

2. Molecular fingerprinting of complex allergoids – Erika Jensen-Jarolim, Institute of Pathophysiology and Allergy Research, Medical University Vienna.

3. Rationale for broad spectrum grass immunotherapy – Uwe Berger, Medical University of Vienna. Head of Aerobiology & Pollen Information Research Unit.

4. Defining the plateau of the efficacy for Allergen Specific Immunotherapy – Tim Higenbottam, R&D Director, Allergy Therapeutics.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.